Risk factors and clinical impact of cytomegalovirus DNAemia in patients with multiple myeloma treated with teclistamab

Risk factors and clinical impact of cytomegalovirus DNAemia in patients with multiple myeloma treated with teclistamab

Saved in:

Bibliographic Details
Main Authors:	Charles Pei, Zeinab El Boghdadly, Lisa Blackburn, Nidhi Sharma, Naresh Bumma, Abdullah M. Khan, Srinivas Devarakonda, Elvira Umyarova, Don Benson, Ashley Rosko, Francesca Cottini
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Series:	Blood Neoplasia
Online Access:	http://www.sciencedirect.com/science/article/pii/S2950328025000329
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era
by: Megan Broughton, et al.
Published: (2025-06-01)

Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
by: Lisa Blackburn, et al.
Published: (2024-10-01)

Cytomegalovirus Blood DNAemia in Patients with Severe SARS-CoV-2 Pneumonia
by: Jean-Baptiste Mesland, et al.
Published: (2025-01-01)

Injection site reaction to teclistamab in a patient with multiple myeloma
by: Isabel C. Yoon, BS, et al.
Published: (2025-02-01)

Impact of cytomegalovirus DNAemia detected by next-generation sequencing on short-term prognosis after lung transplantation
by: Zhongping Xu, et al.
Published: (2025-06-01)

Teclistamab‐Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma
by: Renata Quevedo‐Salazar, et al.
Published: (2025-06-01)

Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
by: Asis Shrestha, et al.
Published: (2025-04-01)

Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment
by: Danai Dima, et al.
Published: (2025-07-01)

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma
by: James A. Davis, et al.
Published: (2025-03-01)

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
by: Carlyn Rose Tan, et al.
Published: (2025-04-01)

Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis
by: Wenze Li, et al.
Published: (2025-04-01)

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
by: Elvira Umyarova, et al.
Published: (2025-03-01)

Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients
by: Farheen Chunara, et al.
Published: (2025-04-01)

Manifestations of Teclistamab‐Associated Uveitis
by: Gabriel Castilho Barbosa, et al.
Published: (2025-06-01)

Sequential Myelomatous Pleural and Pericardial Effusions in Multiple Myeloma: A Case Report Demonstrating Extended Survival with Teclistamab
by: Deena Mudawi, et al.
Published: (2025-05-01)

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
by: Oren Pasvolsky, et al.
Published: (2025-05-01)

Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
by: Danai Dima, et al.
Published: (2025-06-01)

Epstein-Barr virus (EBV) DNAemia in saliva of viral encephalitis and nasopharyngeal carcinoma patients
by: Nanditha Srinivasan, et al.
Published: (2025-01-01)

Case Report: Reactive T-cell large granular lymphocytes in the bone marrow of a patient with relapsed/refractory multiple myeloma receiving teclistamab
by: Erin A. Dean, et al.
Published: (2025-08-01)

Teclistamab for heavily pretreated relapsed / refractory POEMS syndrome
by: Alexis Talbot, et al.
Published: (2025-07-01)

Single-Center Outcomes of Epstein–Barr Virus DNAemia in Adult Solid Organ Transplant Recipients
by: Sara W. Dong, et al.
Published: (2024-01-01)

Teclistamab <i>versus</i> B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis
by: Junmin Song, et al.
Published: (2025-04-01)

MONITORAMENTO DOS EFEITOS ADVERSOS DO TECLISTAMABE: PAPEL DA ENFERMAGEM
by: VMS Moraes, et al.
Published: (2024-10-01)

Risk Prediction and Management of BKPyV-DNAemia in Kidney Transplant Recipients: A Multicenter Analysis of Immunosuppressive Strategies
by: Jin-Myung Kim, et al.
Published: (2025-07-01)

Cytomegalovirus Retinitis Associated with Lenalidomide Use for Multiple Myeloma in an Immunocompetent Patient
by: Matthew K. Adams, et al.
Published: (2019-01-01)

Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens
by: Danilo De Novellis, et al.
Published: (2024-07-01)

Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
by: Carlyn Rose Tan, et al.
Published: (2025-07-01)

Time to initiation of antiresorptive agents in multiple myeloma to reduce skeletal related events
by: Amman Bhasin, et al.
Published: (2025-02-01)

WCN25-1014 TECLISTAMAB AND NIVOLUMAB: A SYNERGISTIC KIDNEY STORM - A CASE OF ACUTE INTERSTITIAL NEPHRITIS WITH DUAL IMMUNOTHERAPY
by: Arjunmohan Mohan, et al.
Published: (2025-02-01)

Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial
by: Hans Salwender, et al.
Published: (2024-12-01)

Intrathecal Administration of High-Titer Cytomegalovirus Immunoglobulin for Cytomegalovirus Meningitis
by: Shin-ichiro Fujiwara, et al.
Published: (2014-01-01)

IMPACT OF PRETRANSPLANT DONOR AND RECIPIENT CYTOMEGALOVIRUS SEROSTATUS ON OUTCOME FOR MULTIPLE MYELOMA PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION.
by: Jean Elcheikh
Published: (2013-04-01)

Cytomegalovirus DNA in the nails of an infant diagnosed with a congenital cytomegalovirus infection
by: Haruki Komatsu, et al.
Published: (2020-08-01)

Cytomegalovirus genetic diversity
by: O. E. Vankova, et al.
Published: (2017-06-01)

Comparison of Hearing Phenotypes Among Children With Congenital Cytomegalovirus and Other Non‐Cytomegalovirus Conditions
by: Shi Liang, et al.
Published: (2025-04-01)

PARAMETERS OF ANTIVIRAL IMMUNITY IN NEWBORNS WITH CYTOMEGALOVIRUS INFECTION IN CASES OF LATE DETECTION OF CYTOMEGALOVIRUS DNA
by: L. V. Kravchenko
Published: (2018-09-01)

Prevalence and phylogenetic analysis of cytomegalovirus (Orthoherpesviridae: <i>Cytomegalovirus: Cytomegalovirus humanbeta5</i>) genetic variants from children and immunocompromised patients in central Russia
by: Ol’ga E. Van’kova, et al.
Published: (2024-12-01)

The problem of congenital cytomegalovirus infection
by: R. A. Ivanova, et al.
Published: (2016-07-01)

Human cytomegalovirus and neonatal infection
by: Shelley M. Lawrence
Published: (2024-01-01)

RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA
by: Ugo Testa, et al.
Published: (2024-06-01)